These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 28839265)

  • 21. (-)-Epigallocatechin-3-gallate downregulates estrogen receptor alpha function in MCF-7 breast carcinoma cells.
    Farabegoli F; Barbi C; Lambertini E; Piva R
    Cancer Detect Prev; 2007; 31(6):499-504. PubMed ID: 18061364
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tamoxifen induces the expression of maspin through estrogen receptor-alpha.
    Liu Z; Shi HY; Nawaz Z; Zhang M
    Cancer Lett; 2004 Jun; 209(1):55-65. PubMed ID: 15145521
    [TBL] [Abstract][Full Text] [Related]  

  • 23. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
    Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
    Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activation of FOXO3a by the green tea polyphenol epigallocatechin-3-gallate induces estrogen receptor alpha expression reversing invasive phenotype of breast cancer cells.
    Belguise K; Guo S; Sonenshein GE
    Cancer Res; 2007 Jun; 67(12):5763-70. PubMed ID: 17575143
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genome-Wide Analysis on Transcriptome and Methylome in Prevention of Mammary Tumor Induced by Early Life Combined Botanicals.
    Arora I; Li S; Crowley MR; Li Y; Tollefsbol TO
    Cells; 2022 Dec; 12(1):. PubMed ID: 36611809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Leptin attenuates the anti-estrogen effect of tamoxifen in breast cancer.
    Chen X; Zha X; Chen W; Zhu T; Qiu J; Røe OD; Li J; Wang Z; Yin Y
    Biomed Pharmacother; 2013 Feb; 67(1):22-30. PubMed ID: 23199901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Arsenic trioxide re-sensitizes ERα-negative breast cancer cells to endocrine therapy by restoring ERα expression in vitro and in vivo.
    Zhang W; Wang L; Fan Q; Wu X; Wang F; Wang R; Ma Z; Yang J; Lu SH
    Oncol Rep; 2011 Sep; 26(3):621-8. PubMed ID: 21687957
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of MAP kinase promotes the recruitment of corepressor SMRT by tamoxifen-bound estrogen receptor alpha and potentiates tamoxifen action in MCF-7 cells.
    Hong W; Chen L; Li J; Yao Z
    Biochem Biophys Res Commun; 2010 May; 396(2):299-303. PubMed ID: 20406620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Z-ligustilide restores tamoxifen sensitivity of ERa negative breast cancer cells by reversing MTA1/IFI16/HDACs complex mediated epigenetic repression of ERa.
    Ma H; Li L; Dou G; Wang C; Li J; He H; Wu M; Qi H
    Oncotarget; 2017 Apr; 8(17):29328-29345. PubMed ID: 28415616
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
    Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
    Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genistein sensitizes inhibitory effect of tamoxifen on the growth of estrogen receptor-positive and HER2-overexpressing human breast cancer cells.
    Mai Z; Blackburn GL; Zhou JR
    Mol Carcinog; 2007 Jul; 46(7):534-42. PubMed ID: 17295235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells.
    Herynk MH; Beyer AR; Cui Y; Weiss H; Anderson E; Green TP; Fuqua SA
    Mol Cancer Ther; 2006 Dec; 5(12):3023-31. PubMed ID: 17172405
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro and in vivo effects of combination of Trastuzumab (Herceptin) and Tamoxifen in breast cancer.
    Wang CX; Koay DC; Edwards A; Lu Z; Mor G; Ocal IT; Digiovanna MP
    Breast Cancer Res Treat; 2005 Aug; 92(3):251-63. PubMed ID: 16155796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth.
    Britton DJ; Hutcheson IR; Knowlden JM; Barrow D; Giles M; McClelland RA; Gee JM; Nicholson RI
    Breast Cancer Res Treat; 2006 Mar; 96(2):131-46. PubMed ID: 16261397
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Maternal Epigenetic Regulation Contributes to Prevention of Estrogen Receptor-negative Mammary Cancer with Broccoli Sprout Consumption.
    Li S; Chen M; Wu H; Li Y; Tollefsbol TO
    Cancer Prev Res (Phila); 2020 May; 13(5):449-462. PubMed ID: 32184225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined Broccoli Sprouts and Green Tea Polyphenols Contribute to the Prevention of Estrogen Receptor-Negative Mammary Cancer via Cell Cycle Arrest and Inducing Apoptosis in HER2/neu Mice.
    Li S; Wu H; Tollefsbol TO
    J Nutr; 2021 Jan; 151(1):73-84. PubMed ID: 33188406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activity of the antiestrogenic cajanin stilbene acid towards breast cancer.
    Fu Y; Kadioglu O; Wiench B; Wei Z; Wang W; Luo M; Yang X; Gu C; Zu Y; Efferth T
    J Nutr Biochem; 2015 Nov; 26(11):1273-82. PubMed ID: 26365581
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer.
    Wang LH; Yang XY; Zhang X; An P; Kim HJ; Huang J; Clarke R; Osborne CK; Inman JK; Appella E; Farrar WL
    Cancer Cell; 2006 Dec; 10(6):487-99. PubMed ID: 17157789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel prodrug of epigallocatechin-3-gallate: differential epigenetic hTERT repression in human breast cancer cells.
    Meeran SM; Patel SN; Chan TH; Tollefsbol TO
    Cancer Prev Res (Phila); 2011 Aug; 4(8):1243-54. PubMed ID: 21411498
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.
    Hoffmann J; Bohlmann R; Heinrich N; Hofmeister H; Kroll J; Künzer H; Lichtner RB; Nishino Y; Parczyk K; Sauer G; Gieschen H; Ulbrich HF; Schneider MR
    J Natl Cancer Inst; 2004 Feb; 96(3):210-8. PubMed ID: 14759988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.